MONTREAL, QUEBEC: Ibalizumab Maintains Significant Reduction of Viral Load in Patients with Multi-Drug Resistant HIV-1 Over 24 Weeks. Results from the Study Support the Regulatory Submission of the BLA to the US FDA.
...
LYON, FRANCE: Total Revenues Were $32.1 Million; 2016 Revenue Guidance Increased to $133 to $143 Million; REST-ON Phase III Trial of Micropump Sodium Oxybate Initiated
...
HALIFAX, NOVA SCOTIA: Collaboration with UConn Health Completes First Proof-of-Concept for DPX-NEO Program Designed to Develop Patient-specific Neoepitope Immunotherapies
...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.